His scientific interests lie mostly in Pharmacokinetics, Pharmacology, Drug, Physiologically based pharmacokinetic modelling and ADME. The various areas that Amin Rostami-Hodjegan examines in his Pharmacokinetics study include Drug metabolism, Bioavailability, Intestinal absorption, Cytochrome P450 and Physiology. His Pharmacology research incorporates themes from CYP2D6 and Computational biology.
His work carried out in the field of Drug brings together such families of science as Hepatic drug clearance and Adaptive change. His work in Physiologically based pharmacokinetic modelling addresses issues such as Transporter, which are connected to fields such as Rosuvastatin and Rosuvastatin Calcium. His studies deal with areas such as Distribution and Drug discovery as well as ADME.
Amin Rostami-Hodjegan mainly focuses on Pharmacology, Pharmacokinetics, Physiologically based pharmacokinetic modelling, Drug and Biochemistry. Within one scientific family, Amin Rostami-Hodjegan focuses on topics pertaining to CYP2D6 under Pharmacology, and may sometimes address concerns connected to Dextromethorphan. His Pharmacokinetics research includes elements of Bioavailability and Drug metabolism.
His Drug study combines topics from a wide range of disciplines, such as Intensive care medicine, Computational biology, Bioinformatics and Dosing. The various areas that Amin Rostami-Hodjegan examines in his Dosing study include Precision medicine and Medical physics. His research related to Enzyme, Cytochrome P450 and Proteomics might be considered part of Biochemistry.
Amin Rostami-Hodjegan focuses on Drug, Pharmacokinetics, Pharmacology, Physiologically based pharmacokinetic modelling and Dosing. His work on Drug metabolism as part of general Drug research is frequently linked to Clearance, bridging the gap between disciplines. Pharmacokinetics is a subfield of Internal medicine that Amin Rostami-Hodjegan explores.
His research in Pharmacology intersects with topics in Organic anion transporter 1, Transporter, CYP3A4, CYP2C8 and Repaglinide. Amin Rostami-Hodjegan has researched Physiologically based pharmacokinetic modelling in several fields, including ADME, Drug development, Coefficient of variation, Clinical study design and Whole liver. The Dosing study combines topics in areas such as Decision support tools, Precision medicine, Intensive care medicine, Patient-Specific Modeling and Medical physics.
Amin Rostami-Hodjegan mostly deals with Pharmacokinetics, Drug, Physiologically based pharmacokinetic modelling, Pharmacology and Dosing. His Pharmacokinetics study introduces a deeper knowledge of Internal medicine. When carried out as part of a general Drug research project, his work on Drug development and Drug metabolism is frequently linked to work in Dabrafenib, therefore connecting diverse disciplines of study.
His Physiologically based pharmacokinetic modelling research includes themes of Phases of clinical research, Coefficient of variation, CYP3A4, Repaglinide and Bioequivalence. Amin Rostami-Hodjegan combines subjects such as Organic anion transporter 1, Transporter, Quantitative proteomics, Albumin and Tight junction with his study of Pharmacology. His Dosing study integrates concerns from other disciplines, such as Pharmacy, Decision support system, Medical physics and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Amin Rostami-Hodjegan;Geoffrey T. Tucker.
Nature Reviews Drug Discovery (2007)
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
Trevor N Johnson;Amin Rostami-Hodjegan;Amin Rostami-Hodjegan;Geoffrey T Tucker;Geoffrey T Tucker.
Clinical Pharmacokinectics (2006)
The Simcyp® population-based ADME simulator
Masoud Jamei;Steve Marciniak;Kairui Feng;Adrian Barnett.
Expert Opinion on Drug Metabolism & Toxicology (2009)
Population-Based Mechanistic Prediction of Oral Drug Absorption
Masoud Jamei;David Turner;Jiansong Yang;Sibylle Neuhoff.
Aaps Journal (2009)
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.
Zoe E Barter;Martin K Bayliss;Philip H Beaune;Alan R Boobis.
Current Drug Metabolism (2007)
Prediction of intestinal first-pass drug metabolism.
Jiansong Yang;Masoud Jamei;Karen Rowland Yeo;Geoffrey T. Tucker.
Current Drug Metabolism (2007)
Modified-Release Hydrocortisone to Provide Circadian Cortisol Profiles
Miguel Debono;Cyrus Ghobadi;Amin Rostami-Hodjegan;Hiep Huatan.
The Journal of Clinical Endocrinology and Metabolism (2009)
Changes in liver volume from birth to adulthood: A meta‐analysis
Trevor N. Johnson;Geoffrey T. Tucker;Geoffrey T. Tucker;M. Stuart Tanner;Amin Rostami‐Hodjegan;Amin Rostami‐Hodjegan.
Liver Transplantation (2005)
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: A database for parameters required in physiologically based pharmacokinetic modelling
Khaled Abduljalil;Penny Furness;Trevor N. Johnson;Amin Rostami-Hodjegan;Amin Rostami-Hodjegan.
Clinical Pharmacokinectics (2012)
A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates
Masoud Jamei;Gemma L. Dickinson;Amin Rostami-Hodjegan;Amin Rostami-Hodjegan.
Drug Metabolism and Pharmacokinetics (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: